ADC’s Phase II Data May Position ‘Lonca’ To Compete With Roche’s Polivy

 
• By Joseph Haas
  
Lymphoma cancer cell - 3d rendering
ADC Therapeutics thinks Lonca has broad potential across lymphoma settings
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D